Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Common genetic polymorphisms of AURKA and prostate cancer risk.
Feik E, Baierl A, Madersbacher S, Schatzl G, Maj-Hes A, Berges R, Micksche M, Gsur A. Feik E, et al. Cancer Causes Control. 2009 Mar;20(2):147-52. doi: 10.1007/s10552-008-9227-5. Epub 2008 Sep 19. Cancer Causes Control. 2009. PMID: 18802780
Integrative analysis of prostate cancer aggressiveness.
Feik E, Schweifer N, Baierl A, Sommergruber W, Haslinger C, Hofer P, Maj-Hes A, Madersbacher S, Gsur A. Feik E, et al. Prostate. 2013 Sep;73(13):1413-26. doi: 10.1002/pros.22688. Epub 2013 Jun 27. Prostate. 2013. PMID: 23813660
Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer.
Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M, Kramer G, Hartenbach M. Grubmüller B, et al. Among authors: maj hes a. Prostate. 2020 Jan;80(1):74-82. doi: 10.1002/pros.23919. Epub 2019 Oct 15. Prostate. 2020. PMID: 31614001
The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis.
Lucca I, Jichlinski P, Shariat SF, Rouprêt M, Rieken M, Kluth LA, Rink M, Mathieu R, Mbeutcha A, Maj-Hes A, Fajkovic H, Briganti A, Seitz C, Karakiewicz PI, de Martino M, Lotan Y, Babjuk M, Klatte T. Lucca I, et al. Eur Urol Focus. 2016 Apr;2(1):79-85. doi: 10.1016/j.euf.2015.03.001. Epub 2015 May 29. Eur Urol Focus. 2016. PMID: 28723455
Immunotherapies for bladder cancer: a new hope.
Fakhrejahani F, Tomita Y, Maj-Hes A, Trepel JB, De Santis M, Apolo AB. Fakhrejahani F, et al. Curr Opin Urol. 2015 Nov;25(6):586-96. doi: 10.1097/MOU.0000000000000213. Curr Opin Urol. 2015. PMID: 26372038 Free PMC article. Review.
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.
Csizmarik A, Nagy N, Keresztes D, Váradi M, Bracht T, Sitek B, Witzke K, Puhr M, Tornyi I, Lázár J, Takács L, Kramer G, Sevcenco S, Maj-Hes A, Hadaschik B, Nyirády P, Szarvas T. Csizmarik A, et al. Among authors: maj hes a. Prostate Cancer Prostatic Dis. 2023 Aug 26. doi: 10.1038/s41391-023-00713-y. Online ahead of print. Prostate Cancer Prostatic Dis. 2023. PMID: 37634036
21 results